**Amendments to the Claims**:

Please amend Claims 1 and 3-14 as set forth below. Please add new claims 15-23. This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**:

1. (currently amended) Compounds of the general formula **I**




Formula **I**

wherein

Y and Z represent independently from each other hydrogen, fluorine or a methyl group, or Y and Z may together form a cyclopropyl ring;

X represents $-CH_2-CH(K)-CH_2-$; $-CH_2CH_2-$; $-CH_2OCH_2-$; $-CH_2SCH_2-$; $-CH_2SOCH_2-$; $-CH_2SO_2CH_2-$; $-CO-NL-CHR^6-$; $-CHR^6-NL-CO-$;

W represents a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

V represents a bond; $-(CH_2)_r-$; $-A-(CH_2)_s-$; $-CH_2-A-(CH_2)_t-$; $-(CH_2)_s-A-$; $-(CH_2)_2-A-(CH_2)_u-$; $-A-(CH_2)_v-B-$; $-CH_2-CH_2-CH_2-A-CH_2-$; $-A-CH_2-CH_2-B-CH_2-$; $-CH_2-A-CH_2-CH_2-B-$; $-CH_2-CH_2-$

$CH_2$-A-$CH_2$-$CH_2$-; -$CH_2$-$CH_2$-$CH_2$-$CH_2$-A-$CH_2$-; -A-$CH_2$-$CH_2$-B-$CH_2$-$CH_2$-; -$CH_2$-A-$CH_2$-$CH_2$-B-$CH_2$-; -$CH_2$-A-$CH_2$-$CH_2$-$CH_2$-B-;

-$CH_2$-$CH_2$-A-$CH_2$-$CH_2$-B-; –O-$CH_2$-CH($OCH_3$)-$CH_2$-O; -O-$CH_2$-CH($CH_3$)-$CH_2$-O-; -O-$CH_2$-CH($CF_3$)-$CH_2$-O-; -O-$CH_2$-C($CH_3$)$_2$-$CH_2$-O-; -O-$CH_2$-C($CH_3$)$_2$-O-; -O-C($CH_3$)$_2$-$CH_2$-O-; -O-$CH_2$-CH($CH_3$)-O-; -O-CH($CH_3$)-$CH_2$-O-; -O-$CH_2$-C($CH_2CH_2$)-O-; -O-C($CH_2CH_2$)-$CH_2$-O-;

A and B independently represent -O-; -S-; -SO-; -$SO_2$-;

U represents aryl; heteroaryl;

T represents -$CONR^1$-; -$(CH_2)_pOCO$-; -$(CH_2)_pN(R^1)CO$-; -$(CH_2)_pN(R^1)SO_2$-; or

-COO-;

Q represents lower alkylene; lower alkenylene;

M represents aryl-$O(CH_2)_vR^5$; heteroaryl-$O(CH_2)_vR^5$; aryl-$O(CH_2)_2O(CH_2)_wR^5$; heteroaryl-$(CH_2)_2O(CH_2)_wR^5$;

L represents -$R^3$; -$COR^3$; -$COOR^3$; -$CONR^2R^3$; -$SO_2R^3$; -$SO_2NR^2R^3$;

-COCH(Aryl)$_2$;

K represents –H; -$CH_2OR^3$; -$CH_2NR^2R^3$; -$CH_2NR^2COR^3$; -$CH_2NR^2SO_2R^3$; -$CO_2R^3$; -$CH_2OCONR^2R^3$; -$CONR^2R^3$; -$CH_2NR^2CONR^2R^3$; -$CH_2SO_2NR^2R^3$; -$CH_2SR^3$; -$CH_2SOR^3$; -$CH_2SO_2R^3$;

$R^1$ represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

$R^2$ and $R^{2'}$ independently represent hydrogen; lower alkyl; lower alkenyl; cycloalkyl; cycloalkyl - lower alkyl;

$R^3$ represents hydrogen; lower alkyl; lower alkenyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl - lower alkyl; aryl - lower alkyl; heteroaryl - lower alkyl; heterocyclyl - lower alkyl; aryloxy - lower alkyl; heteroaryloxy - lower alkyl, whereby these groups may be unsubstituted or mono-, di- or trisubstituted with hydroxy, $-OCOR^2$, $-COOR^2$, lower alkoxy, cyano, $-CONR^2R^{2'}$, -CO-morpholin-4-yl, -CO-((4-loweralkyl)piperazin-1-yl), $-NH(NH)NH_2$, $-NR^4R^{4'}$ or lower alkyl, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized;

$R^4$ and $R^{4'}$ independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl - lower alkyl; hydroxy - lower alkyl; $-COOR^2$; $-CONH_2$;

$R^5$ represents –OH, $-OCOR^2$, $-COOR^2$, $-NR^2R^{2'}$, $-OCONR^2R^{2'}$, $-NCONR^2R^{2'}$, cyano, $-CONR^2R^{2'}$, $SO_3H$, $-SONR^2R^{2'}$, -CO-morpholin-4-yl, -CO-((4-loweralkyl)piperazin-1-yl), $-NH(NH)NH_2$, $-NR^4R^{4'}$, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized;

$R^6$ represents hydrogen; lower alkyl; lower alkoxy, whereby these groups may be unsubstituted or monosubstituted with hydroxy, $-CONH_2$,
-COOH, imidazoyl, $-NH_2$, -CN, $-NH(NH)NH_2$;

p is the integer 1, 2, 3 or 4;

r is the integer 1, 2, 3, 4, 5, or 6;

s is the integer 1, 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

v is the integer 2, 3, or 4;

w is the integer 1 or 2;

~~and~~ in any form, including optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as free or pharmaceutically acceptable salt~~s~~, solvent complex~~es~~ and morphological forms.

2. (original) Compounds of general formula **I** according to claim 1 wherein Z, Y, W, V, U, T, Q, and M are as defined in general formula **I** and

X represents $-CH_2CH_2-$.

3. (currently amended) Compounds of general formula **I** according to ~~any one of claims~~ claim 1 ~~to 2~~ wherein Z, Y, X, W, V, U, T, Q, and M are as defined in general formula **I** and

L represents H; $-COR^{3''}$; $-COOR^{3''}$; $-CONR^{2''}R^{3''}$;

$R^{2''}$ and $R^{3''}$ represent independently lower alkyl; lower cycloalkyl - lower alkyl, which lower alkyl and lower cycloalkyl-lower alkyl are undubstituted or mono-substituted with halogen, -CN, -OH, $-OCOCH_3$, $-CONH_2$,-COOH, or $-NH_2$, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized.

4. (currently amended) Compounds of general formula **I** according to ~~any one of claims~~ claim 1 ~~to 3~~ wherein Z, Y, X, W, V, and U are as defined in general formula **I** and

T represents $-CONR^{1}-$;

Q represents methylene;

M represents aryl-$O(CH_2)_vR^5$; heteroaryl-$O(CH_2)_vR^5$.

5. (currently amended) Compounds of general formula **I** according to ~~any one of claims~~ claim 1 ~~to 4~~ wherein Z, Y, V, U, T, Q, and M are as defined in general formula **I** and

W represents a 4-substituted phenyl.

6. (currently amended) Compounds of general formula **I** according to ~~any one of claims~~ claim 1 ~~to 5~~ wherein Z, Y, X, W, V, Q, T, and M are as defined in general formula **I** and

U is a mono-, di-, or trisubstituted phenyl whereby the substituents are halogen; lower alkyl or lower alkoxy.

7. (currently amended) Compounds of formula I according to ~~any one of claims~~ claim 1 ~~to 6~~ wherein

Z and Y represent hydrogen;

U represents a tri-substituted phenyl ring substituted independently with halogen or $C_1$-$C_4$-alkyl;

V represents –O-$CH_2$-$CH_2$-$CH_2$-; -O-$CH_2$-$CH_2$-O-; -O-$CH_2$-$CH_2$-; -$CH_2$- $CH_2$-O-; -O-$CH_2$-$CH_2$-$CH_2$-O-; -$CH_2$-$CH_2$-$CH_2$-O-;

W represents a phenyl ring substituted by V in the 4-position and connected to the carbon atom at the double bond of the tetrahydro-pyridin ring in the 1-position;

X represents –$CH_2$-$CH_2$-; -$CH_2$- SO-$CH_2$-; - $CH_2$- $SO_2$-$CH_2$-; -$CH_2$-O-$CH_2$-;

T represents –$CONR^1$-, wherein $R^1$ is a cycloalkyl group;

Q represents –$CH_2$-;

M represents a substituted pyridyl-$O(CH_2)_vR^5$ group substituted with $C_1$-$C_4$-alkyl, wherein $R^5$ is hydroxyl; -$COOR_2$, wherein $R^2$ is hydrogen or $C_1$-$C_4$-alkyl; or –$CONR^2R^{2'}$, wherein $R^2$ and $R^{2'}$ are hydrogen or $C_1$-$C_4$-alkyl.

8. (currently amended) Compounds of formula I according to ~~any one of claims~~ claim 1 ~~to 7~~ wherein

Z and Y represent hydrogen;

U represents a tri-substituted phenyl ring substituted independently with halogen or a phenyl ring substituted in 2- and 6- position with chloro and in 4-position with a methyl group;

V represents $-O-CH_2-CH_2-CH_2-$; $-O-CH_2-CH_2-O-$;

W represents a phenyl ring substituted by V in the 4-position and connected to the carbon atom at the double bond of the tetrahydro-pyridin ring in the 1-position;

X represents $-CH_2-CH_2-$; $-CH_2-SO_2-CH_2-$; $-CH_2-O-CH_2-$;

T represents $-CONR^1-$, wherein $R^1$ is a cyclopropyl group;

Q represents $-CH_2-$;

M represents a pyridinyl-$O(CH_2)_vR^5$ group, whereby the pyridinyl ring is substituted with a methyl group, wherein $R^5$ represents hydroxyl; or $-COOR_2$, wherein $R^2$ is hydrogen or methyl; or $R^5$ is $-CONH_2$ and $_v$ is the integer 2 or 3.

9. (currently amended) The compounds according to ~~any one of claims~~ claim 1 ~~–8~~ selected from the group consisting of

(*rac.*)-(*1R**, *5S**)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide,

(*rac.*)-(*1R**, *5S**)-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide,

(*rac.*)-(*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3$\lambda^6$-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide,

(*rac.*)-(*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxy-propoxy)-3-methylpyridin-4-ylmethyl]amide,

(*rac.*)-(*1R**, *5S**)-3-(4-{[(3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]-phenyl}-8-azabicyclo[3.2.1]oct-2-ene-2-carbonyl)cyclopropylamino]methyl}-3-methyl-pyridin-2-yloxy)propionic acid,

(*rac.*)-(*1R**, *5S**)-3-(4-{[(3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-azabicyclo[3.2.1]oct-2-ene-2-carbonyl)cyclopropylamino]methyl}-3-methyl-pyridin-2-yloxy)propionic acid methyl ester, and

(*rac.*)-(*1R**, *5S**)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid [2-(2-carbamoylethoxy)-3-methyl-pyridin-4-ylmethyl]cyclopropylamide.

10. (currently amended) Compounds of the general formula **I**




Formula **I**

wherein

Y and Z represent independently from each other hydrogen, fluorine or a methyl group, or Y and Z may together form a cyclopropyl ring; in case k represents the integer 1, Y and Z both represent hydrogen;

X represents $-(CH_2)_m$-N(L)-$(CH_2)_m$-; -$CH_2$-CH(K)-$CH_2$-; -$CH_2CH_2$-; -$CH_2OCH_2$-; -$CH_2SCH_2$-; -$CH_2SOCH_2$-; -$CH_2SO_2CH_2$-; -CO-NL-CO-; -CO-NL-$CHR^6$-; -$CHR^6$-NL-CO-;

W represents a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in position 3 or 4;

V represents a bond; $-(CH_2)_r$-; -A-$(CH_2)_s$-; -$CH_2$-A-$(CH_2)_t$-; $-(CH_2)_s$-A-; $-(CH_2)_2$-A-$(CH_2)_u$-; -A-$(CH_2)_v$-B-; -$CH_2$-$CH_2$-$CH_2$-A-$CH_2$-; -A-$CH_2$-$CH_2$-B-$CH_2$-; -$CH_2$-A-$CH_2$-$CH_2$-B-; -$CH_2$-$CH_2$-$CH_2$-A-$CH_2$-$CH_2$-; -$CH_2$-$CH_2$-$CH_2$-$CH_2$-A-$CH_2$-; -A-$CH_2$-$CH_2$-B-$CH_2$-$CH_2$-; -$CH_2$-A-$CH_2$-$CH_2$-B-$CH_2$-; -$CH_2$-A-$CH_2$-$CH_2$-$CH_2$-B-; or -$CH_2$-$CH_2$-A-$CH_2$-$CH_2$-B-; –O-$CH_2$-CH($OCH_3$)-$CH_2$-O; -O-$CH_2$-CH($CH_3$)-$CH_2$-O-; -O-$CH_2$-CH($CF_3$)-$CH_2$-O-; -O-$CH_2$-C($CH_3$)$_2$-$CH_2$-O-; -O-$CH_2$-C($CH_3$)$_2$-O-; -O-C($CH_3$)$_2$-$CH_2$-O-; -O-$CH_2$-CH($CH_3$)-O-; -O-CH($CH_3$)-$CH_2$-O-; -O-$CH_2$-C($CH_2CH_2$)-O-; -O-C($CH_2CH_2$)-$CH_2$-O-;

A and B independently represent -O-; -S-; -SO-; -$SO_2$-;

U represents aryl; heteroaryl;

T represents -$CONR^1$-; $-(CH_2)_pOCO$-; $-(CH_2)_pN(R^1)CO$-; $-(CH_2)_pN(R^1)SO_2$-; or -COO-;

Q represents lower alkylene; lower alkenylene;

M represents aryl-$O(CH_2)_vR^5$; heteroaryl-$O(CH_2)_vR^5$; aryl-$O(CH_2)_2O(CH_2)_wR^5$; heteroaryl-$(CH_2)_2O(CH_2)_wR^5$;

L represents -$R^3$; -$COR^3$; -$COOR^3$; -$CONR^2R^3$; -$SO_2R^3$; -$SO_2NR^2R^3$;

-$COCH(Aryl)_2$;

K represents –H; -$CH_2OR^3$; -$CH_2NR^2R^3$; -$CH_2NR^2COR^3$; -$CH_2NR^2SO_2R^3$; -$CO_2R^3$; -$CH_2OCONR^2R^3$; -$CONR^2R^3$; -$CH_2NR^2CONR^2R^3$; -$CH_2SO_2NR^2R^3$; -$CH_2SR^3$; -$CH_2SOR^3$; -$CH_2SO_2R^3$;

$R^1$ represents hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

$R^2$ and $R^{2'}$ independently represent hydrogen; lower alkyl; lower alkenyl; cycloalkyl; cycloalkyl - lower alkyl;

$R^3$ represents hydrogen; lower alkyl; lower alkenyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl - lower alkyl; aryl - lower alkyl; heteroaryl - lower alkyl; heterocyclyl - lower alkyl; aryloxy - lower alkyl; heteroaryloxy - lower alkyl, whereby these groups may be unsubstituted or mono-, di- or trisubstituted with hydroxy, -$OCOR^2$, -$COOR^2$, lower alkoxy, cyano, -$CONR^2R^{2'}$, -CO-morpholin-4-yl, -CO-((4-loweralkyl)piperazin-1-yl), -$NH(NH)NH^2$, -$NR^4R^{4'}$ or lower alkyl, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized;

$R^4$ and $R^{4'}$ independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl - lower alkyl; hydroxy - lower alkyl; -$COOR^2$; -$CONH_2$;

$R^5$ represents –OH, -$OCOR^2$, -$COOR^2$, -$NR^2R^{2'}$, -$OCONR^2R^{2'}$, -$NCONR^2R^{2'}$, cyano, -$CONR^2R^{2'}$, $SO_3H$, -$SONR^2R^{2'}$, -CO-morpholin-4-yl, -CO-((4-loweralkyl)piperazin-1-yl), -$NH(NH)NH_2$, -$NR^4R^{4'}$, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp3-hybridized;

$R^6$ represents hydrogen; lower alkyl; lower alkoxy, whereby these groups may be unsubstituted or monosubstituted with hydroxy, -$CONH_2$,
-COOH, imidazoyl, -$NH_2$, -CN, -$NH(NH)NH_2$;

k is the integer 0 or 1;

m and n represent the integer 0 or 1, with the proviso that in case m represents the integer 1, n is the integer 0; in case n represents the integer 1, m is the integer 0; in case k represents the integer 0, n represents the integer 0; in case X does not represent –$(CH_2)_m$-N(L)-$(CH_2)_m$-, n represnts the integer 0;

p is the integer 1, 2, 3 or 4;

r is the integer 1, 2, 3, 4, 5, or 6;

s is the integer 1, 2, 3, 4, or 5;

t is the integer 1, 2, 3, or 4;

u is the integer 1, 2, or 3;

v is the integer 2, 3, or 4;

w is th integer 1 or 2;

~~and~~ in any form including optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of

diastereomeric racemates, and the meso-form; as well as free or pharmaceutically acceptable salts, solvent complexes and morphological forms.

11. (currently amended) Pharmaceutical compositions containing comprising a compound of any one of claims claim 1 –10 and usual in combination or association with pharmaceutically acceptable carrier materials and or adjuvants. for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases, hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.

12. (currently amended) A method for the treatment or prophylaxis of diseases which are related to the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases which are related to the RAS, which method comprises administrating administering an effective amount of a compound according to any one of claims claim 1 to 10 to a human being or animal.

13. (currently amended) The use of compounds according to any one of claims 1 to 10 Pharmaceutical compositions comprising a compound of claim 10 in combination or association

with a pharmaceutically acceptable carrier or adjuvant. ~~for the treatment or prophylaxis of diseases which are associated with the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS.~~

14. (currently amended) ~~The use of one or more compounds of any one of claims claim 1 to 10 in combination with other pharmacologically active compounds comprising~~ A method according to claim 12 further comprising administering of an effective amount of a second pharmacologically active compound selected from ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists~~,~~ and alpha-adrenergic antagonists. ~~, for the treatment of disorders as set forth in any one of claims 10 to 13.~~

15. (new) A method for the treatment or prophylaxis of diseases which are related to the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases which are related to the RAS, which method comprises administering an effective amount of a compound according to claim 10 to a human being or animal.

16. (new) A method according to claim 15 further comprising administering of an effective amount of a second pharmacologically active compound selected from ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta-adrenergic antagonists and alpha-adrenergic antagonists.

17. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

18. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-3-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

19. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3,3-dioxo-3$\lambda^6$-thia-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxypropoxy)-3-methylpyridin-4-ylmethyl]amide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

20. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-7-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-[2-(3-hydroxy-propoxy)-3-methylpyridin-4-ylmethyl]amide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

21. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-3-(4-{[(3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]-phenyl}-8-azabicyclo[3.2.1]oct-2-ene-2-carbonyl)cyclopropylamino]methyl}-3-methyl-pyridin-2-yloxy)propionic acid, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

22. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-3-(4-{[(3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-azabicyclo[3.2.1]oct-2-ene-2-carbonyl)cyclopropylamino]methyl}-3-methyl-pyridin-2-yloxy)propionic acid methyl ester, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.

23. (new) A compound according to claim 1 which is (*rac.*)-(*1R**, *5S**)-3-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-8-aza-bicyclo[3.2.1]oct-2-ene-2-carboxylic acid [2-(2-carbamoylethoxy)-3-methyl-pyridin-4-ylmethyl]cyclopropylamide, or a single enantiomer thereof, in free or pharmaceutically acceptable salt form.